zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie
['cll', 'zilovertamab', 'lymsm', 'leusm']
zilovertamab/ibrutinib elicits durable responses with favorable tolerability in mcl and cll #ash22 #lymsm #leusm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.